01 / DESIGN
What was studied?
Seventy-one patients with heart failure and reduced ejection fraction were randomized in a double-blind comparison of elamipretide and placebo. Cardiac magnetic resonance imaging assessed left-ventricular end-systolic volume after four weeks.
02 / FINDINGS
What did the researchers report?
Changes in the primary ventricular-volume measurement did not differ significantly between either active group and placebo. Ejection-fraction changes also did not show a significant group difference in the reported analysis.
03 / LIMITS
How should it be interpreted?
A plausible mitochondrial mechanism does not guarantee a measurable clinical response. The brief exposure period and specific heart-failure population limit what this neutral trial can exclude, but the result should not be rewritten as proof of benefit or transferred to other formulations.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.